48.98
price up icon2.00%   0.96
after-market 시간 외 거래: 48.93 -0.05 -0.10%
loading
전일 마감가:
$48.02
열려 있는:
$49.0203
하루 거래량:
6.73M
Relative Volume:
0.47
시가총액:
$99.68B
수익:
$47.64B
순이익/손실:
$5.42B
주가수익비율:
18.34
EPS:
2.67
순현금흐름:
$13.09B
1주 성능:
+3.84%
1개월 성능:
+4.39%
6개월 성능:
-17.18%
1년 성능:
+13.96%
1일 변동 폭
Value
$48.83
$49.05
1주일 범위
Value
$46.57
$49.05
52주 변동 폭
Value
$43.25
$63.33

브리스톨 마이어스 스퀴브 Stock (BMY) Company Profile

Name
명칭
Bristol Myers Squibb Co
Name
전화
(609) 252-4621
Name
주소
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Name
직원
34,100
Name
트위터
@BMSNEWS
Name
다음 수익 날짜
2024-10-31
Name
최신 SEC 제출 서류
Name
BMY's Discussions on Twitter

BMY을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
BMY
Bristol Myers Squibb Co
48.98 97.72B 47.64B 5.42B 13.09B 2.67
Drug Manufacturers - General icon
LLY
Lilly Eli Co
798.89 697.04B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
169.10 404.05B 90.63B 22.66B 18.57B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
190.55 330.51B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
117.97 226.17B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
70.03 296.73B 43.59B 15.04B 10.74B 3.3766

브리스톨 마이어스 스퀴브 Stock (BMY) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-22 개시 Cantor Fitzgerald Neutral
2025-04-22 개시 Piper Sandler Overweight
2024-12-16 업그레이드 Jefferies Hold → Buy
2024-12-10 재개 BofA Securities Neutral
2024-11-15 개시 Wolfe Research Peer Perform
2024-11-13 업그레이드 Daiwa Securities Neutral → Outperform
2024-11-12 업그레이드 Leerink Partners Market Perform → Outperform
2024-10-25 다운그레이드 Citigroup Buy → Neutral
2024-10-17 개시 Bernstein Mkt Perform
2024-07-29 다운그레이드 Barclays Overweight → Equal Weight
2024-03-11 다운그레이드 Societe Generale Buy → Hold
2024-02-06 다운그레이드 Redburn Atlantic Buy → Neutral
2024-01-03 다운그레이드 BofA Securities Buy → Neutral
2023-11-15 다운그레이드 Cantor Fitzgerald Overweight → Neutral
2023-11-09 개시 Deutsche Bank Hold
2023-11-02 다운그레이드 Daiwa Securities Outperform → Neutral
2023-10-27 다운그레이드 BMO Capital Markets Outperform → Market Perform
2023-10-27 업그레이드 HSBC Securities Reduce → Hold
2023-10-27 다운그레이드 William Blair Outperform → Mkt Perform
2023-10-20 재개 UBS Neutral
2023-07-14 개시 HSBC Securities Reduce
2023-07-10 개시 SVB Securities Market Perform
2023-06-28 개시 Daiwa Securities Outperform
2023-03-06 개시 Jefferies Hold
2023-01-17 개시 Cantor Fitzgerald Overweight
2022-11-18 개시 Credit Suisse Neutral
2022-10-10 다운그레이드 Guggenheim Buy → Neutral
2022-09-14 다운그레이드 Berenberg Buy → Hold
2022-06-03 다운그레이드 Raymond James Outperform → Mkt Perform
2022-04-06 재개 Morgan Stanley Underweight
2021-12-17 개시 Goldman Buy
2021-12-09 재개 Wells Fargo Equal Weight
2021-11-19 개시 BMO Capital Markets Outperform
2021-11-01 다운그레이드 Argus Buy → Hold
2021-07-27 재개 Truist Buy
2021-04-30 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2021-04-13 업그레이드 Truist Hold → Buy
2020-11-16 업그레이드 Societe Generale Hold → Buy
2020-11-10 재개 Bernstein Mkt Perform
2020-11-06 다운그레이드 Gabelli & Co Buy → Hold
2020-10-19 업그레이드 Guggenheim Neutral → Buy
2020-09-29 개시 Berenberg Buy
2020-07-28 개시 Raymond James Outperform
2020-04-02 업그레이드 Morgan Stanley Equal-Weight → Overweight
2020-03-23 다운그레이드 Societe Generale Buy → Hold
2020-02-27 개시 Barclays Equal Weight
2020-01-06 재개 Citigroup Buy
2019-12-13 업그레이드 Argus Hold → Buy
2019-11-22 재개 Morgan Stanley Equal-Weight
2019-10-17 재개 BofA/Merrill Buy
2019-08-14 업그레이드 Atlantic Equities Neutral → Overweight
2019-05-28 개시 Goldman Buy
2019-05-20 다운그레이드 Argus Buy → Hold
2019-05-03 업그레이드 Barclays Equal Weight → Overweight
2019-05-03 재개 JP Morgan Overweight
2019-01-15 업그레이드 Societe Generale Sell → Buy
2018-10-22 다운그레이드 Citigroup Buy → Neutral
모두보기

브리스톨 마이어스 스퀴브 주식(BMY)의 최신 뉴스

pulisher
Jul 23, 2025

Rheumatologists Eye AbbVie’s Rinvoq, Roche/Genentech’s Gazyva, and Bristol Myers Squibb’s Sotyktu as Front-Runners to Address Persistent Gaps in Systemic Lupus Erythematosus Care, Spherix Global Insights Reports - GlobeNewswire Inc.

Jul 23, 2025
pulisher
Jul 23, 2025

Jim Cramer on Bristol-Myers: “Never Seen it This Cheap” - Insider Monkey

Jul 23, 2025
pulisher
Jul 23, 2025

Dr Reddy's kicks off India big pharma earnings with narrow profit miss - Reuters

Jul 23, 2025
pulisher
Jul 23, 2025

Citi Keeps Their Hold Rating on Bristol-Myers Squibb (BMY) - The Globe and Mail

Jul 23, 2025
pulisher
Jul 23, 2025

Bristol-Myers Squibb’s Promising CELMoD Pipeline and Revenue Growth Potential: Analyst Buy Rating - TipRanks

Jul 23, 2025
pulisher
Jul 22, 2025

Bristol Myers Squibb Company Stock Analysis and ForecastOutstanding stock performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Bristol Myers Squibb Application for Psoriatic Arthritis Drug Accepted for Review in Four Regions - PharmTech

Jul 22, 2025
pulisher
Jul 22, 2025

Shareholders in Bristol-Myers Squibb (NYSE:BMY) are in the red if they invested three years ago - simplywall.st

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Bristol Myers Squibb Company stock priceFree Advanced Stock Screener Access - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

What analysts say about Bristol Myers Squibb Company stockExceptional financial outcomes - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

Lobbying Update: $4,780,000 of BRISTOL-MYERS SQUIBB COMPANY lobbying was just disclosed - Quiver Quantitative

Jul 21, 2025
pulisher
Jul 21, 2025

Bristol-Myers Squibb Company (BMY): All Or Nothing With A Breakthrough Drug, Says Jim Cramer - MSN

Jul 21, 2025
pulisher
Jul 21, 2025

FDA accepts Bristol Myers Squibb’s application for Sotyktu in psoriatic arthritis By Investing.com - Investing.com South Africa

Jul 21, 2025
pulisher
Jul 21, 2025

FDA Review: Bristol Myers' Sotyktu Could Become First TYK2 Inhibitor for Psoriatic Arthritis - Stock Titan

Jul 21, 2025
pulisher
Jul 21, 2025

Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace

Jul 21, 2025
pulisher
Jul 21, 2025

Jim Cramer Reflected on These 17 Stocks - Insider Monkey

Jul 21, 2025
pulisher
Jul 20, 2025

Bristol Myers Squibb Stock (BMY) Opinions on Phase 3 Trial Results - Quiver Quantitative

Jul 20, 2025
pulisher
Jul 20, 2025

What analysts say about Bristol Myers Squibb Company Equity Right stockFree Stock Selection - Autocar Professional

Jul 20, 2025
pulisher
Jul 18, 2025

Why Income Investors Are Watching Bristol-Myers Squibb Company (BMY) in 2025 - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers' Drug Flunks Blood Cancer-Associated Anemia Trial - AOL.com

Jul 18, 2025
pulisher
Jul 18, 2025

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia - insights.citeline.com

Jul 18, 2025
pulisher
Jul 18, 2025

Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb (BMY), Sets a $34 PT - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Pfizer (PFE) and Bristol Myers (BMY) Launch Direct-to-Patient Eliquis Program - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers drug fails main goal in cancer-linked anemia trial - Reuters

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol-Myers Squibb stock holds steady as Reblozyl study misses endpoint - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers Squibb Announces Topline Results from Phase 3 INDEPENDENCE Trial for Reblozyl® (luspatercept-aamt) in Adult Patients with Myelofibrosis-Associated Anemia - BioSpace

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers' drug fails main goal in cancer-related anemia trial - Reuters

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers' drug fails main goal in late-stage trial for cancer-related anemia - Reuters

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers late-stage trial for anemia drug fails (BMY) - Seeking Alpha

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers Squibb’s Reblozyl misses primary endpoint in myelofibrosis trial By Investing.com - Investing.com South Africa

Jul 18, 2025
pulisher
Jul 18, 2025

Bristol Myers Squibb’s Reblozyl misses primary endpoint in myelofibrosis trial - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Boomers Get a Big Beautiful Tax Break: 4 Safe Stocks Yielding 5% to Buy Now - 24/7 Wall St.

Jul 18, 2025
pulisher
Jul 18, 2025

BMS, Pfizer take DTC route for blood thinner Eliquis - pharmaphorum

Jul 18, 2025
pulisher
Jul 18, 2025

13 Cheap Stocks Under $50 to Buy Now - Insider Monkey

Jul 18, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to US patients - Reuters

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off - Benzinga

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers Squibb and Pfizer Launch Online Discount Program for Eliquis Blood Thinner - geneonline.com

Jul 17, 2025
pulisher
Jul 17, 2025

Major drugmakers offer big discount on blood thinner Eliquis - Fox Business

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol-Myers Squibb: Morgan Stanley highlights catalyst driven idea By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol-Myers Squibb: Morgan Stanley highlights catalyst driven idea - Investing.com

Jul 17, 2025
pulisher
Jul 17, 2025

BMS/Pfizer Offer Direct-to-Consumer Option for Eliquis - Managed Healthcare Executive

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients - Reuters

Jul 17, 2025
pulisher
Jul 17, 2025

How Bristol Myers Squibb and Pfizer's Direct-to-Patient Eliquis Initiative is Reshaping Anticoagulant Access and Profitability - AInvest

Jul 17, 2025
pulisher
Jul 17, 2025

Drugmakers to Sell Popular Blood Thinner Eliquis at 40% Discount - Bloomberg.com

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers Squibb and Pfizer Announce Direct-to-Patient Eliquis® (apixaban) Option - BioSpace

Jul 17, 2025
pulisher
Jul 17, 2025

Bristol Myers, Pfizer Slash Eliquis Price by 40% with New Direct-to-Patient Program for Top Blood Thinner - Stock Titan

Jul 17, 2025
pulisher
Jul 16, 2025

BROKERS’ NOTES: Buy Novo Nordisk, sell Bristol Myers Squibb - BusinessLIVE

Jul 16, 2025
pulisher
Jul 16, 2025

Will Increased Expenses Affect Bristol Myers' Performance? - The Globe and Mail

Jul 16, 2025
pulisher
Jul 16, 2025

Key facts about Nik Jhangiani, Diageo's new interim CEO - Reuters

Jul 16, 2025
pulisher
Jul 15, 2025

Bristol-Myers Squibb’s KarXT Study: A Potential Game-Changer in Schizophrenia Treatment - TipRanks

Jul 15, 2025
pulisher
Jul 15, 2025

Bristol-Myers Squibb’s New Alzheimer’s Study: A Potential Game Changer? - TipRanks

Jul 15, 2025

브리스톨 마이어스 스퀴브 (BMY) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
drug_manufacturers_general SNY
$50.16
price up icon 2.89%
$113.56
price up icon 3.08%
drug_manufacturers_general PFE
$25.36
price up icon 0.88%
$309.22
price up icon 1.15%
drug_manufacturers_general MRK
$83.98
price up icon 2.90%
drug_manufacturers_general NVO
$70.03
price up icon 4.87%
자본화:     |  볼륨(24시간):